Best Penny Stocks Under 10 Cents Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. These penny stocks all have a super-low share price of $0.10 or less and are sorted by average trading volume in dollars. These companies are considered the most actively-traded stocks priced under $0.10.

Show:
Fisker stock logo

#1 - Fisker

NYSE:FSR
Stock Price:
$0.09 (-$0.04)
P/E Ratio:
-0.04
Market Cap:
$31.45 million
Average Trading Volume:
85.29 million shares
Consensus Rating:
Reduce (1 Buy Ratings, 4 Hold Ratings, 4 Sell Ratings)
Consensus Price Target:
$2.76 (2,972.0% Upside)
Fisker Inc. develops, manufactures, markets, leases, or sells electric vehicles. It operates through three segments: The White Space, The Value Segment, and The Conservative Premium segments. The company is also involved in asset-light automotive business. In addition, it offers fisker flexible platform agnostic design, a process that develops and designs electric vehicles in specific segment size. The company was incorporated in 2016 and is headquartered in Manhattan Beach, California.
Sintx Technologies stock logo

#2 - Sintx Technologies

NASDAQ:SINT
Stock Price:
$0.04
P/E Ratio:
-0.01
Market Cap:
$862,000.00
Average Trading Volume:
21.72 million shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Atreca stock logo

#3 - Atreca

NASDAQ:BCEL
Stock Price:
$0.09 (+$0.01)
P/E Ratio:
-0.03
Market Cap:
$3.37 million
Average Trading Volume:
6.83 million shares
Consensus Rating:
Hold (0 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.00 (4,605.9% Upside)
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.
Pineapple Energy stock logo

#4 - Pineapple Energy

NASDAQ:PEGY
Stock Price:
$0.05 (-$0.01)
P/E Ratio:
-0.03
Market Cap:
$3.27 million
Average Trading Volume:
3.97 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.50 (5,358.5% Upside)
Pineapple Energy Inc. engages in the sale, design, and installation of photovoltaic solar energy systems and battery storage systems in the United States. Its brand portfolio includes SUNation, Hawaii Energy Connection, E-Gear, Sungevity, and Horizon Solar Power. The company develops and manufactures energy management software and hardware, such as energy management control devices on solar systems that are paired with batteries. It primarily serves residential homeowners, as well as commercial owners, other municipal customers, energy services companies, and other utilities. Pineapple Energy Inc. was founded in 1969 and is based in Minnetonka, Minnesota.
Gamida Cell stock logo

#5 - Gamida Cell

NASDAQ:GMDA
Stock Price:
$0.02
P/E Ratio:
-0.03
Market Cap:
$2.55 million
Average Trading Volume:
9.20 million shares
Consensus Rating:
Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.75 (28,644.3% Upside)
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
CURO Group stock logo

#6 - CURO Group

NYSE:CURO
Stock Price:
$0.09 (-$0.01)
P/E Ratio:
-0.01
Market Cap:
$3.61 million
Average Trading Volume:
984,281 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$3.00 (3,328.6% Upside)
CURO Group Holdings Corp., together with its subsidiaries, provides consumer finance products in the United States and Canada. The company offers secured and unsecured installment loans, revolving line of credit, and single-pay loans; and credit protection insurance, check cashing, money transfer, foreign currency exchange, and other ancillary financial products and services, as well as reloadable prepaid debit cards and demand deposit accounts. The company also provides loans through online. It operates under the Covington Credit, Heights Finance, Quick Credit, Southern Finance, First Heritage Credit, Cash Money, LendDirect, and Flexiti brands. The company was formerly known as Speedy Group Holdings Corp. and changed its name to CURO Group Holdings Corp. in May 2016. CURO Group Holdings Corp. was founded in 1997 and is headquartered in Chicago, Illinois.
Invitae stock logo

#7 - Invitae

NYSE:NVTA
Stock Price:
$0.00
P/E Ratio:
0.00
Market Cap:
$401,000.00
Average Trading Volume:
23.72 million shares
Consensus Rating:
Strong Sell (0 Buy Ratings, 0 Hold Ratings, 3 Sell Ratings)
Consensus Price Target:
$1.00 (66,566.7% Upside)
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Sonendo stock logo

#8 - Sonendo

NYSE:SONX
Stock Price:
$0.09
P/E Ratio:
-0.15
Market Cap:
$6.47 million
Average Trading Volume:
273,166 shares
Consensus Rating:
Hold (1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$1.88 (1,880.8% Upside)
Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment, a technology platform designed for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid EDTA that is used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software to enable an integrated digital office for dental practitioners. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. The company was incorporated in 2006 and is headquartered in Laguna Hills, California.
Nevada Copper stock logo

#9 - Nevada Copper

OTCMKTS:NEVDF
Stock Price:
$0.07 (-$0.02)
Average Trading Volume:
314,379 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Nevada Copper Corp. engages in the exploration, development, and operation of mineral properties in Nevada. The company explores for copper, iron magnetite, gold, and silver ores. It holds 100% interests in the Pumpkin Hollow property that consist of approximately 24,300 acres of contiguous mineral rights located in northwestern Nevada, the United States. Nevada Copper Corp. was incorporated in 1999 and is based in Vancouver, British Columbia.
Motus GI stock logo

#10 - Motus GI

NASDAQ:MOTS
Stock Price:
$0.07 (-$0.01)
P/E Ratio:
0.00
Market Cap:
$380,000.00
Average Trading Volume:
306,078 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$28.88 (41,150.0% Upside)
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida.
Nextech3D.AI stock logo

#11 - Nextech3D.AI

OTCMKTS:NEXCF
Stock Price:
$0.10
Market Cap:
$12.94 million
Average Trading Volume:
174,741 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$0.50 (419.8% Upside)
Nextech3D.AI Corporation provides augmented reality technologies, wayfinding technologies, and 3D model services. It focuses on creating 3D WebAR photorealistic models for the prime ecommerce marketplace, as well as other online retailers. The company was formerly known as NexTech AR Solutions Corp. and changed its name to Nextech3D.AI Corporation in September 2023. Nextech3D.AI Corporation was incorporated in 2018 and is headquartered in Toronto, Canada.
Evofem Biosciences stock logo

#12 - Evofem Biosciences

NASDAQ:EVFM
Stock Price:
$0.02
P/E Ratio:
0.00
Market Cap:
$830,000.00
Average Trading Volume:
719,923 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Aridis Pharmaceuticals stock logo

#13 - Aridis Pharmaceuticals

NASDAQ:ARDS
Stock Price:
$0.06
P/E Ratio:
-0.40
Market Cap:
$3.09 million
Average Trading Volume:
102,590 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.00 (3,000.8% Upside)
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
Movella stock logo

#14 - Movella

NASDAQ:MVLA
Stock Price:
$0.02
Market Cap:
$1.17 million
Average Trading Volume:
226,426 shares
Consensus Rating:
Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.45 (10,552.2% Upside)
Movella Holdings Inc. operates as a full-stack provider of sensors, software, and analytics that enable the digitization of movement in the United States. Its real-time character movement in digital environments transforms movement into digital data that provides actionable insights. The company offers Xsens 3D Body Motion Systems comprises wearable sensor systems and motion capture solutions, including MVN Animate or MVN Analyze software, a full-body wearable sensor system, which captures the motion of the human body. It also provides Xsens sensor modules that enables customers to accelerate the development of motion-based applications; and DOT wearables for analysis and reporting of human kinematics. In addition, the company offers Kinduct human performance platform that provides biomechanical, biometric, and objective data for athletic performance, wellness, and injury risk. It serves the entertainment, health and sports, and automation and mobility markets. Movella Holdings Inc. is based in Henderson, Nevada.
Meyer Burger Technology stock logo

#15 - Meyer Burger Technology

OTCMKTS:MYBUF
Stock Price:
$0.01 (+$0.00)
Average Trading Volume:
340,830 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Meyer Burger Technology AG, a technology company, produces and sells solar cells and modules. It operates through Photovoltaics and Modules segments. The company offers its products based on proprietary Heterojunction/SmartWire technologies. It operates in Germany, Switzerland, rest of Europe, Asia, the United States, and internationally. Meyer Burger Technology AG was founded in 1953 and is headquartered in Thun, Switzerland.
Reliq Health Technologies stock logo

#16 - Reliq Health Technologies

OTCMKTS:RQHTF
Stock Price:
$0.05 (+$0.02)
P/E Ratio:
-5.00
Market Cap:
$6.71 million
Average Trading Volume:
97,150 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Reliq Health Technologies Inc., a healthcare technology company, develops secure telemedicine and virtual care solutions for the healthcare market. It offers iUGO Care platform, a software as a solution that allows complex patients to receive care in the home. The company was formerly known as Moseda Technologies Inc. and changed its name to Reliq Health Technologies Inc. in May 2016. Reliq Health Technologies Inc. was incorporated in 2005 is headquartered in Hamilton, Canada.
Better Therapeutics stock logo

#17 - Better Therapeutics

NASDAQ:BTTX
Stock Price:
$0.01
P/E Ratio:
-0.01
Market Cap:
$310,000.00
Average Trading Volume:
746,041 shares
Consensus Rating:
Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$6.00 (98,260.7% Upside)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Bellerophon Therapeutics stock logo

#18 - Bellerophon Therapeutics

NASDAQ:BLPH
Stock Price:
$0.05
P/E Ratio:
-0.06
Market Cap:
$625,000.00
Average Trading Volume:
62,212 shares
Consensus Rating:
Hold (0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.00 (3,813.9% Upside)
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

#19 - SQZ Biotechnologies

OTCMKTS:SQZB
Stock Price:
$0.05
P/E Ratio:
-0.02
Market Cap:
$1.42 million
Average Trading Volume:
37,058 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Evelo Biosciences stock logo

#20 - Evelo Biosciences

NASDAQ:EVLO
Stock Price:
$0.04 (-$0.01)
P/E Ratio:
0.00
Market Cap:
$940,000.00
Average Trading Volume:
26,414 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Labrador Iron Mines stock logo

#21 - Labrador Iron Mines

OTCMKTS:LBRMF
Stock Price:
$0.04
Average Trading Volume:
21,717 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Labrador Iron Mines Holdings Limited, a mineral resource company, engages in the exploration, development, and mining of iron ore projects in Canada. Its flagship project is the Houston project, which is an open pit direct shipping iron ore project located near the town of Schefferville. The company was incorporated in 2007 and is headquartered in Toronto, Canada.
MetaWorks Platforms stock logo

#22 - MetaWorks Platforms

OTCMKTS:MWRK
Stock Price:
$0.03
Market Cap:
$2.21 million
Average Trading Volume:
36,150 shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
MetaWorks Platforms, Inc. provides blockchain and Web3 development platform. It offers turnkey set of services for companies to develop and integrate blockchain and cryptocurrency technologies into their business operations. The company provides business development and technical services; blockchain and technology program management services; customer development services; business launch services; and post-business launch support services. The company was formerly known as CurrencyWorks Inc. and changed its name to MetaWorks Platforms, Inc. in August 2022. MetaWorks Platforms, Inc. was incorporated in 2010 and is based in Fairfield, California.
Nemaura Medical stock logo

#23 - Nemaura Medical

NASDAQ:NMRD
Stock Price:
$0.07 (-$0.01)
P/E Ratio:
-0.18
Market Cap:
$3.39 million
Average Trading Volume:
10,956 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.50 (3,372.2% Upside)
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Eguana Technologies stock logo

#24 - Eguana Technologies

OTCMKTS:EGTYF
Stock Price:
$0.01
Average Trading Volume:
65,216 shares
Consensus Rating:
Hold (0 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$0.90 (8,900.0% Upside)
Eguana Technologies Inc. designs and manufactures residential and commercial energy storage systems for fuel cell, photovoltaic, and battery applications in Canada, Asia, Australia, Europe, and the United States. The company provides its products under the Enduro, Evolve, and Elevate brand names. The company was formerly known as Sustainable Energy Technologies Ltd. and changed its name to Eguana Technologies Inc. in September 2013. Eguana Technologies Inc. is headquartered in Calgary, Canada.

#25 - KWG Group

OTCMKTS:KWGPF
Stock Price:
$0.06
Average Trading Volume:
10,000 shares
Consensus Rating:
Sell (0 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
N/A
KWG Group Holdings Limited, together with its subsidiaries, engages in the property development and investment, and hotel operation businesses. Its property portfolio includes mid- to high-end residential properties, serviced apartments, villas, offices, hotels, and shopping malls. The company was formerly known as KWG Property Holding Limited and changed its name to KWG Group Holdings Limited in August 2018. KWG Group Holdings Limited was founded in 1995 and is headquartered in Guangzhou, the People's Republic of China.

More Stock Ideas from MarketBeat